Lung cancer, despite modern trends in the development of medical oncology and science, remains one of the key tasks of clinical medicine. On the one hand, this is due to the fact that the overwhelming number of patients at the time of initial diagnosis have an unresectable/inoperable stage of the disease, on the other hand, the latest predictive indicators in the world still indicate a high incidence of morbidity and mortality in terms of the structure of cancer incidence. In this regard, there is an urgent need to find alternative ways to treat the malignant process, including drug therapy. Drug therapy for lung cancer in the world today is represented by an extensive list of optional cytostatics, targeted agents, and immunoages.

All of 22 patients aged 52 to 60 years were treated in the period from 2022 to 2024. In all patients, stage IIIa-IIIb of the process was established (T3N0M0 – T2-3bN1M0). All patients at the time of initial or repeated treatment (relapse) had a histologically verified variant of non-small cell lung cancer. Morphologically, lung adenocarcinoma was detected in 5 patients (22.7%), squamous cell carcinoma was detected in 17 patients (77.3%). In all cases, radiological confirmation of the local extent of the process was noted through CT/MRI/PET/CT examinations. All patients received intra-arterial chemotherapy in the branch of the bronchial artery according to the “TR” regimen (Docetaxel 75 mg/m2 + Cisplatin 75 mg/m2) in a standard therapeutic dose.The interval between courses of intra-arterial chemotherapy was carried out once every 21 days from the date of administration of chemotherapy. Among the side effects, one can note the inherent cytotoxicity of the drugs with manifestations of anemia, leukemia and thrombocytopenia, which were corrected through the use of L-CSF (leukocyte colony-stimulating factor), glucocorticoids and targeted symptomatic replacement therapy. We present the results of our own empirical observations of patients in the above cohort.